EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pretreatment Amide Proton Transfer‐Weighted Imaging Histogram Analysis Combined With ER ‐Negative and HER2 ‐Positive Expression Predicts Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer

Mingzhe Xu iD, Dongqiu Shan, Xuejun Chen, Renzhi Zhang, Chunmiao Xu, Jing Li, Zhiwei Shen, Yue Wu, Jinrong Qu

Cancer Medicine · 2025

DOI: 10.1002/cam4.71420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Mingzhe Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Receptors, Estrogen, Magnetic Resonance Imaging. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Construction Project of the Medical Science and Technology Research Program of Henan Province, China, National High Level Hospital Clinical Research Funding and National Cancer Center Climbing Fund..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the predictive value of pre‐treatment histogram analysis using APTWI, diffusion‐weighted imaging (DWI), and early contrast‐enhanced silhouette imaging in determining pathological complete response (pCR) post‐NAC in breast cancer, and to investigate whether combining immunohistochemical indicators enhances predictive accuracy. Materials and Methods A retrospective continuous collection of 108 females with breast cancer who underwent NAC and pre‐treatment APTWI, DWI, and dynamic contrast‐enhanced imaging at our hospital. Clinical, MRI imaging, and pathological characteristics were analyzed for patients. NAC response was divided into pCR and non‐pCR. Tumor segmentation and histogram feature extraction were performed on APT, ADC, and early contrast‐enhanced silhouette images, and combined them with clinical features to construct an NAC efficacy prediction model. Diagnostic performance was assessed using receiver operating characteristic curves, with DeLong's test employed to compare areas under the curve (AUC).

Results

In pCR group, mean, root‐mean‐square deviation, and 5th, 10th, 15th, 25th, 50th, 75th, 85th percentile of MTRasym, along with 1st percentiles of ADC were significantly higher in the pCR group than in the non‐pCR group ( p < 0.05). Conversely, the interquartile range of MTRasym and 10th percentiles of ADC were significantly lower in the pCR group ( p < 0.05). ER‐negative, HER2‐positive expression, and 5th percentile MTRasym value were identified as independent predictors of pCR post‐NAC (odds ratios, 0.16, 7.25, and 1.35, respectively). The combined diagnostic model demonstrated an AUC of 0.844, significantly outperforming individual parameters ( p < 0.05).

Conclusion

Pre‐treatment histogram analysis of MTRasym values derived from APTWI provides significant predictive value for pCR post‐NAC in breast cancer. The combined diagnostic model incorporating APTWI with ER and HER2 expression status further enhances diagnostic performance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenMagnetic Resonance ImagingHumansFemaleNeoadjuvant TherapyMiddle AgedRetrospective StudiesAdultAgedTreatment OutcomeDiffusion Magnetic Resonance ImagingROC CurveAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorPrognosisPathologic Complete Response

Stichwörter der Autor:innen

amide proton transferbreast cancerdiffusion weighted imagingneoadjuvant chemotherapypathological complete response

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • The Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • The Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Philips Healthcare, Beijing, China.

ORCID-Profile: Mingzhe Xu

Förderung

  • Joint Construction Project of the Medical Science and Technology Research Program of Henan Province, China
  • National High Level Hospital Clinical Research Funding and National Cancer Center Climbing Fund.

Zitieren

APA

Xu, M., Shan, D., Chen, X., Zhang, R., Xu, C., Li, J., Shen, Z., Wu, Y., & Qu, J. (2025). Pretreatment Amide Proton Transfer‐Weighted Imaging Histogram Analysis Combined With ER ‐Negative and HER2 ‐Positive Expression Predicts Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71420

Vancouver

Xu M, Shan D, Chen X, Zhang R, Xu C, Li J, et al. Pretreatment Amide Proton Transfer‐Weighted Imaging Histogram Analysis Combined With ER ‐Negative and HER2 ‐Positive Expression Predicts Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.71420

BibTeX
@article{Xu2025,
  author = {Xu, Mingzhe and Shan, Dongqiu and Chen, Xuejun and Zhang, Renzhi and Xu, Chunmiao and Li, Jing and Shen, Zhiwei and Wu, Yue and Qu, Jinrong},
  title = {Pretreatment Amide Proton Transfer‐Weighted Imaging Histogram Analysis Combined With ER ‐Negative and HER2 ‐Positive Expression Predicts Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71420}
}
Kostenlos starten →